Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1968 3
1969 1
1970 2
1971 1
1972 1
1973 1
1989 2
1991 1
1992 1
1993 2
1994 1
1995 2
1996 6
1997 1
1998 3
2000 3
2001 1
2006 1
2007 2
2008 4
2009 2
2010 3
2011 3
2012 7
2013 10
2014 17
2015 8
2016 4
2017 2
2018 2
2019 2
2020 9
2021 8
2022 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Results by year

Filters applied: . Clear all
Page 1
Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.
Okumura K, Akao M, Yoshida T, Kawata M, Okazaki O, Akashi S, Eshima K, Tanizawa K, Fukuzawa M, Hayashi T, Akishita M, Lip GYH, Yamashita T; ELDERCARE-AF Committees and Investigators. Okumura K, et al. N Engl J Med. 2020 Oct 29;383(18):1735-1745. doi: 10.1056/NEJMoa2012883. Epub 2020 Aug 30. N Engl J Med. 2020. PMID: 32865374 Clinical Trial.
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H; AFIRE Investigators. Yasuda S, et al. N Engl J Med. 2019 Sep 19;381(12):1103-1113. doi: 10.1056/NEJMoa1904143. Epub 2019 Sep 2. N Engl J Med. 2019. PMID: 31475793 Clinical Trial.
Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial.
Naito R, Miyauchi K, Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H; AFIRE Investigators. Naito R, et al. JAMA Cardiol. 2022 Aug 1;7(8):787-794. doi: 10.1001/jamacardio.2022.1561. JAMA Cardiol. 2022. PMID: 35704345 Free PMC article. Clinical Trial.
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, Komura N, Sakamoto K, Oka H, Nakao K, Nakamura S, Ishihara M, Matsui K, Sakaino N, Nakamura N, Yamamoto N, Koide S, Matsumura T, Fujimoto K, Tsunoda R, Morikami Y, Matsuyama K, Oshima S, Kaikita K, Hokimoto S, Ogawa H; PRECISE–IVUS Investigators. Tsujita K, et al. J Am Coll Cardiol. 2015 Aug 4;66(5):495-507. doi: 10.1016/j.jacc.2015.05.065. J Am Coll Cardiol. 2015. PMID: 26227186 Free article. Clinical Trial.
Validation of the obesity paradox by body mass index and waist circumference in patients undergoing percutaneous coronary intervention.
Shirahama Y, Tabata N, Sakamoto K, Sato R, Yamanaga K, Fujisue K, Sueta D, Araki S, Takashio S, Arima Y, Hokimoto S, Sato K, Sakamoto T, Nakao K, Shimomura H, Matsumura T, Tayama S, Fujimoto K, Oshima S, Nakamura S, Tsunoda R, Hirose T, Kikuta K, Sakaino N, Yamamoto N, Kajiwara I, Suzuki S, Yamamoto E, Kaikita K, Matsushita K, Tsujita K; Kumamoto Intervention Conference Study (KICS) Investigators. Shirahama Y, et al. Among authors: tayama s. Int J Obes (Lond). 2022 Oct;46(10):1840-1848. doi: 10.1038/s41366-022-01163-7. Epub 2022 Jul 28. Int J Obes (Lond). 2022. PMID: 35902692
109 results